In this issue:
Dual SGLT-1/2 inhibition with sotagliflozin in T1DM
Adding semaglutide vs. sitagliptin in T2DM uncontrolled with metformin/sulfonylurea
Long-term weight loss with metformin or lifestyle intervention
Dapagliflozin ±saxagliptin in T2DM and CKD
Data-driven subgroups versus clinical feature models for T2DM progression/response
Suspend-before-low insulin pump technology in hypoglycaemia-prone T1DM
Primary care-led weight-management intervention for T2DM
Semaglutide added to SGLT-2 inhibitor in T2DM
Structured SMBG ±TeleCare support in non-insulin treated T2DM
Physical exercise and intermittently viewed CGM performance in T1DM
Please login below to download this issue (PDF)